Abstract: Objective To compare the efficacy and safety of amisulpride and risperidone in the treatment of schizophrenia with negative symptoms.Methods Patients with schizophrenia who were hospitalized in Mental Health Center of Hebei Province were included in the study. Patients who met the inclusion criteria and did not meet the exclusion criteria were randomly assigned to the amisulpride group and the risperidone group(35 cases in each group ). Positive and negative symptom scales(PANSS), negative symptom scales(SANS), clinical overall impression scale(CGI-S), and side effects scale(TESS)were evaluated at the time of enrollment, 4 weeks, and 8 weeks. Results Thirty-two patients in the amisulpride group were examined and 31 patients in the risperidone group were determined. The dose of amisulpride group was(665.63±167.74)mg and the dose of risperidone group was(4.32±0.98)mg. PANSS negative symptom scores and SANS scores in the amisulpride group were lower than those in the risperidone group at 4 and 8 weekends(P<0.05). PANSS, SANS, and CGI-S scores were compared at 8 weeks. The scores were decreased when enrolled, and the difference was statistically significant(P<0.05). There were no serious adverse reactions in the two groups. The adverse reactions were different(56.25% vs. 67.74%, χ²=0.882, P=0.348). The amisulpride group mainly relied on adverse reactions such as secretory, weight gain, tremor, and dry mouth. Risperidone was mainly caused by adverse reactions such as tremor, sedation, constipation, and tachycardia. Conclusion Both amisulpride and risperidone can improve the efficacy of negative symptoms as schizophrenia, but amisulpride is more effective in improving negative symptoms.

Key words: schizophrenia, negative symptoms, amisulpride, risperidone